Sort by
Previous Page Page 1 of 1 Next Page
  1. Research article

    Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography

    The somatostatin receptor subtype 2 (sstr2) is expressed on a majority of luminal breast cancers, however SPECT and scintigraphy imaging with agonistic sstr2 probes has been sub-optimal. High affinity antagoni...

    Iulia Dude, Zhengxing Zhang, Julie Rousseau, Navjit Hundal-Jabal, Nadine Colpo, Helen Merkens, Kuo-Shyan Lin and François Bénard

    EJNMMI Radiopharmacy and Chemistry 2017 2:4

    Published on: 17 April 2017

  2. Research article

    Synthesis, gallium labelling and characterization of P04087, a functionalized phosphatidylserine-binding peptide

    Radiolabeled phosphatidylserine (PS)-binding peptides represent an innovative strategy for molecular imaging of apoptosis and thrombus. The hexapeptide PGDLSR was described as a selective and high affinity lig...

    Rana Ben Azzouna, Alexandre Guez, Khadija Benali, Faisal Al-Shoukr, Walter Gonzalez, Philippe Karoyan, François Rouzet and Dominique Le Guludec

    EJNMMI Radiopharmacy and Chemistry 2017 2:3

    Published on: 7 February 2017

  3. Research

    [64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model

    The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-t...

    Andreas Poschenrieder, Margret Schottelius, Theresa Osl, Markus Schwaiger and Hans-Jürgen Wester

    EJNMMI Radiopharmacy and Chemistry 2017 2:2

    Published on: 19 January 2017

  4. Research

    Preclinical validations of [18F]FPyPEGCBT-c(RGDfK): a 18F-labelled RGD peptide prepared by ligation of 2-cyanobenzothiazole and 1,2-aminothiol to image angiogenesis

    αVβ3, αVβ5 and α5β1 integrins are known to be involved in carcinogenesis and are overexpressed in many types of tumours compared to healthy tissues; thereby they have been selected as promising therapeutic target...

    Didier J. Colin, James A. H. Inkster, Stéphane Germain and Yann Seimbille

    EJNMMI Radiopharmacy and Chemistry 2016 1:16

    Published on: 25 October 2016

  5. Research

    Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid

    Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in ...

    M. Meckel, R. Bergmann, M. Miederer and F. Roesch

    EJNMMI Radiopharmacy and Chemistry 2016 1:14

    Published on: 23 September 2016

  6. Review

    Strategies to facilitate the discovery of novel CNS PET ligands

    Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclini...

    Lei Zhang and Anabella Villalobos

    EJNMMI Radiopharmacy and Chemistry 2016 1:13

    Published on: 13 September 2016

  7. Meeting abstracts

    18th European Symposium on Radiopharmacy and Radiopharmaceuticals

    OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets

    V. Radchenko, J. W. Engle, C. Roy, J. Griswold, M. F. Nortier, E. R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M. E. Fassbender, Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo, Ait-Mohand Samia…

    EJNMMI Radiopharmacy and Chemistry 2016 1(Suppl 1):10

    Published on: 17 June 2016

    This article is part of a Supplement: Volume 1 Supplement 1

  8. Review

    New protein deposition tracers in the pipeline

    Traditional nuclear medicine ligands were designed to target cellular receptors or transporters with a binding pocket and a defined structure–activity relationship. More recently, tracers have been developed t...

    Aleksandar Jovalekic, Norman Koglin, Andre Mueller and Andrew W. Stephens

    EJNMMI Radiopharmacy and Chemistry 2016 1:11

    Published on: 2 June 2016

  9. Research

    Optimizing labelling conditions of 213Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy

    213Bismuth (213Bi, T1/2 = 45.6 min) is one of the most frequently used α-emitters in cancer research. High specific activity radioligands are required for peptide receptor radionuclide...

    Ho Sze Chan, Erik de Blois, Mark W. Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P. Norenberg, Fred J. Verzijlbergen, Marion de Jong and Wouter A. P. Breeman

    EJNMMI Radiopharmacy and Chemistry 2016 1:9

    Published on: 14 May 2016

  10. Research

    44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations

    Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this st...

    Katharina A. Domnanich, Cristina Müller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen

    EJNMMI Radiopharmacy and Chemistry 2016 1:8

    Published on: 5 May 2016

  11. Research

    Improved GMP-compliant multi-dose production and quality control of 6-[18F]fluoro-L-DOPA

    6-[18F]Fluoro-L-3,4-dihydroxyphenylalanine (FDOPA) is a frequently used radiopharmaceutical for detecting neuroendocrine and brain tumors and for the differential diagnosis of Parkinson’s disease. To meet the dem...

    G. Luurtsema, H. H. Boersma, M. Schepers, A. M. T. de Vries, B. Maas, R. Zijlma, E. F. J. de Vries and P. H. Elsinga

    EJNMMI Radiopharmacy and Chemistry 2016 1:7

    Published on: 4 April 2016

  12. Letter to the Editor

    Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics

    149Tb represents a powerful alternative to currently used α-emitters: the relatively short half-life (T1/2 = 4.1 h), low α-energy (3.97 MeV, Iα = 16.7 %), absence of α-emitting daughters ...

    Cristina Müller, Christiaan Vermeulen, Ulli Köster, Karl Johnston, Andreas Türler, Roger Schibli and Nicholas P. van der Meulen

    EJNMMI Radiopharmacy and Chemistry 2016 1:5

    Published on: 28 March 2016

  13. Position paper

    Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals

    This is a position paper of the Radiopharmacy Committee of the EANM (European Association of Nuclear Medicine) addressing toxicology studies for application of new diagnostic and therapeutic radiopharmaceutica...

    J. Koziorowski, M. Behe, C. Decristoforo, J. Ballinger, P. Elsinga, V. Ferrari, P. Kolenc Peitl, S. Todde and T. L. Mindt

    EJNMMI Radiopharmacy and Chemistry 2016 1:1

    Published on: 21 March 2016

  14. Research

    Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission

    Phosphodiesterase 10A (PDE10A) is an important regulator of nigrostriatal dopamine (DA) neurotransmission. However, little is known on the effect of alterations in DA neurotransmission on PDE10A availability. ...

    Maarten Ooms, Sofie Celen, Ronald De Hoogt, Ilse Lenaerts, Johnny Liebregts, Greet Vanhoof, Xavier Langlois, Andrey Postnov, Michel Koole, Alfons Verbruggen, Koen Van Laere and Guy Bormans

    EJNMMI Radiopharmacy and Chemistry 2016 1:3

    Published on: 21 March 2016

Previous Page Page 1 of 1 Next Page

Upcoming events


Related websites

Searching for an article? Easily browse the EJNMMI journals on the Nuclear Medicine and Molecular Imaging webportal.